| E
|
| Drug |
CYP interaction |
Clinical consequences |
| ebrotidine
| 3A4 : inhibits
| ? significance [Clin Pharmacol Ther 1999 Apr;65(4):369-76]
|
| econazole
| 2e1 : inhibits (Ki ~ 4-20 µM) [Xenobiotica 1998 Mar;28(3):293-301]
| ?
|
| 'ecstasy' : see amphetamine
|
| efavirenz (an HIV NNRTI)
| 3A4 : mild induction
| potential for interaction with other anti-retrovirals e.g. indinavir, saquinavir
|
| enalapril
| 3A4 : metabolism
| ?
|
| encainide
| 2D6 : metabolism
| potential for toxicity
|
| enflurane
| CYP2E1 : METABOLISM
| ?
|
| enoxacin (see also Quinolones)
| CYP1A2 : INHIBITS
| clinically significant [Clin Pharmacol Ther 1999 Mar;65(3):262-74]
eg. theophylline
|
| epipodophyllotoxins: see also etoposide, teniposide
| 3A4 : metabolism
| see 3A4.
|
| epirubicin
| ?
| interaction with cimetidine! [Clin Oncol (R Coll Radiol) 1998;10(1):35-8]
|
| ergotamine, dihydroergotamine
| 3A4 : METABOLISM
| ergotism occurs with 3A4 inhibitors
even with a single dose of ergotamine tartrate! [ Postgrad Med J 1999 Sep;75(887):546-7],
and even 5 days of clarithromycin Rx [Arch Intern Med 1996 Feb 26;156(4):456-8]
|
| 3A4 : inhibits
| May interact with eg zonisamide, tacrolimus, cyclosporine.
|
| estradiol (see also ethinylestradiol)
| CYP1A2
| ?
|
| 3A4 : substrate
| ?
|
erythromycin
( See macrolides)
| CYP3A4 : metabolism (NOT 3A5 !)
| ?
|
| 3A4 : INHIBITS
| Clinically relevant : a host of drugs!
|
| ethanol ('alcohol')
| CYP2C9 : ? induces
| ?
|
| CYP2E1 : METABOLISM
| interactions with eg. disulfiram
|
| CYP2E1 ( chronic intake INDUCES, acute INHIBITS )
| may increase e.g. paracetamol
hepatotoxicity
|
| ethinylestradiol
| CYP3A4 : metabolism
| 3A4 induction can reduce effectiveness of oral contraceptives
e.g. oxcarbazepine; also perhaps with
rifampin or rifabutin,
and ritonavir
(interaction with HIV protease inhibitors )
NO interaction with lansoprazole [Int J Clin Pharmacol Ther 1997 Jan;35(1):14-8]
|
| 3A4 : possible inhibition
| ?
|
| ethosuximide
| 3A4 : METABOLISM (no inhibition)
| interaction potential with other anticonvulsants, probably clinically relevant,
and e.g. rifampicin
|
| etomidate
| ? 2E1 : INHIBITS
at concentrations of 0.3mM
| {? impaired EDHF release }
|
| CYP17 : inhibits
| ?
|
| CYP11B1 : potently inhibits
{more so than ketoconazole }
| 'adrenal suppression'
|
| etoposide
| 3A4 : metabolism (and 1A2, 2E1 to a minor degree)
[J Pharmacol Exp Ther 1998 Sep;286(3):1294-300]
| potential for clinical interaction with 3A4 inhibitors
|